FAKTOR OPTIONSSCHEIN - VERTEX PHARMACEUTICALS | Real-time BOERSE MUENCHEN 09:25:25 21/06/2024 BST | ||
| 18.65 EUR | +0.59% |
|
| Current month | +10.03% | ||
| 1 month | +11.22% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 21/06/24 | 18.65 | +0.59% |
| 20/06/24 | 18.54 | +1.81% |
| 19/06/24 | 18.21 | -1.03% |
| 18/06/24 | 18.4 | -3.06% |
| 17/06/24 | 18.98 | -2.52% |
Real-time BOERSE MUENCHEN
Last update June 21, 2024 at 09:25 am
More quotesStatic data
| Product type | Exotische Produkte |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | Goldman Sachs |
| WKN | GK8UJT |
| ISIN | DE000GK8UJT1 |
| Date issued | 08/08/2022 |
| Strike | 233.6 $ |
| Maturity | Unlimited |
| Parity | 11.92 : 1 |
| Emission price | 10.02 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 19.59 € |
|---|---|
| Lowest since issue | 8.36 € |
| Spread | 0.15 € |
| Spread % | 0.80% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
471.4
USD
Average target price
463.4
USD
Spread / Average Target
-1.69%
- Stock Market
- Certificates
- Certificat
